Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name PDGFRB rearrange
Gene Variant Detail

PDGFRB rearrange (unknown)

Relevant Treatment Approaches PDGFR Inhibitor (Pan) PDGFR-beta Inhibitor

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
PDGFRB rearrange myelodysplastic/myeloproliferative neoplasm sensitive PDGFR Inhibitor (Pan) Imatinib FDA approved - On Companion Diagnostic Actionable Gleevec (imatinib) is FDA approved for myelodysplastic/myeloproliferative cancers that are associated with PDGFRB rearrangements and detected by a companion diagnostic (FDA.gov). detail... detail... detail...
PDGFRB rearrange Advanced Solid Tumor predicted - sensitive PDGFR Inhibitor (Pan) Imatinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing a PDGFRB rearrangement were sensitive to treatment with Gleevec (imatinib), demonstrating decreased colony formation and reduced cell growth in culture (PMID: 31645346). 31645346
PDGFRB rearrange myeloid and lymphoid neoplasms associated with PDGFRB rearrangement sensitive PDGFR Inhibitor (Pan) Imatinib Guideline Actionable Gleevec (imatinib) is included in guidelines for patients with a myeloid/lymphoid neoplasm with eosinophilia harboring a PDGFRB rearrangement (NCCN.org). detail...
PDGFRB rearrange childhood B-cell acute lymphoblastic leukemia not applicable N/A Guideline Prognostic PDGFRB rearrangements are associated with a poor prognosis in pediatric patients with B-cell acute lymphoblastic leukemia (NCCN.org). detail...
PDGFRB rearrange B-cell acute lymphoblastic leukemia not applicable N/A Guideline Prognostic PDGFRB rearrangements are associated with a poor prognosis in patients with B-cell acute lymphoblastic leukemia (NCCN.org). detail...
PDGFRB rearrange chronic myelomonocytic leukemia sensitive PDGFR Inhibitor (Pan) Imatinib Guideline Actionable Gleevec (imatinib) is included in guidelines for patients with chronic myelomonocytic leukemia harboring a PDGFRB rearrangement (NCCN.org). detail...